Clinical Trials Browser

Not yet recruiting × Esophageal Squamous Cell Carcinoma × 90 days × Clear all

NCT07623642 2026-06-03

A Phase II Study of GV20-0251 in Combination With Anti-PD-1 Monoclonal Antibodies in Patients With Unresectable, Locally Advanced, or Metastatic Solid Tumors.

BreastGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Gallbladder Neoplasms, Prostatic Neoplasms, Colorectal Neoplasms, Cholangiocarcinoma, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT07621601 2026-06-02

A Study of HS-20093 in Patients With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC)

Phase 3 Not yet recruiting

494 enrolled

Gastrointestinal

Esophageal Squamous Cell Carcinoma, Neoplasm Metastasis

NCT07618910 2026-06-01

Retlirafusp Alfa Plus Chemotherapy as Neoadjuvant Therapy for Thoracic ESCC

Phase 2 Not yet recruiting

33 enrolled

Gastrointestinal

Esophageal Squamous Cell Carcinoma

NCT07602842 2026-05-22

A Study of IDP-001 in Advanced or Metastatic Solid Tumors

Phase 1/2 Not yet recruiting

132 enrolled

GastrointestinalHead & Neck

Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Anus Neoplasms, Carcinoma, Squamous Cell, Neoplasm Metastasis

NCT07573397 2026-05-07

A Prospective Study of Tumor-specific Tpex in Negative Lymph Nodes for Predicting Pathological Complete Response to Neoadjuvant PD 1 Therapy in Esophageal Cancer

Not yet recruiting

88 enrolled

Gastrointestinal

Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms

NCT07554456 2026-04-28

A Study of BL-B01D1 in Combination With Tislelizumab ±5-Fluorouracil Versus Platinum-Based Chemotherapy Plus Tislelizumab as First-line Treatment in Patients With Unresectable, Locally Advanced Recurrent or Metastatic Esophageal Squamous Cell Carcinoma(PANKU-Esophagus02)

Phase 2/3 Not yet recruiting

90 enrolled

Gastrointestinal

Esophageal Squamous Cell Carcinoma

NCT07244978 2026-04-24

Neoadjuvant Ivonescimab（AK112） Combined With Chemotherapy in Patients With Resectable Esophageal Squamous Cell Carcinoma

Phase 2 Not yet recruiting

49 enrolled

Gastrointestinal

Esophageal Squamous Cell Carcinoma

NCT07533357 2026-04-16

Tpex Subsets in Negative Tumor Draining Lymph Nodes for Predicting the Efficacy of PD 1 Inhibitors in Advanced or Recurrent Esophageal Squamous Cell Carcinoma

Not yet recruiting

158 enrolled

Gastrointestinal

Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms

NCT07505186 2026-04-01

Camrelizumab, Chemotherapy and Ivarmacitinib in Patients With Resectable Esophageal Squamous Cell Carcinoma

Phase 2 Not yet recruiting

45 enrolled

Gastrointestinal

Esophageal Squamous Cell Carcinoma

NCT06971848 2026-03-30

ETCABIO

Phase NA Not yet recruiting

70 enrolled

GastrointestinalLymphoidOther hematologic neoplasmOther solid neoplasmPlasma cellThoracic

Immunoglobulin Light-chain Amyloidosis, Esophageal Squamous Cell Carcinoma, Mesothelioma, Malignant, Carcinoma, Bronchogenic, Heart Neoplasms, Carcinoma, Hepatocellular, Lymphoma, Follicular, Colorectal Neoplasms, Leukemia, Lymphocytic, Chronic, B-Cell, Cholangiocarcinoma, Neoplasms, Plasma Cell

NCT07482774 2026-03-19

TME-ESCC

Not yet recruiting

12 enrolled

Gastrointestinal

Esophageal Squamous Cell Carcinoma